259 - Tau, p-tau and beta amiloid 1-42 concentrationsin Alzheimer and frontotemporal dementia patients
Autor(s): M. Zabeo, F. de Rino, F. Rispoli, F. Somalvico, E. Longhi, M. Franceschi
Issue: RIMeL - IJLaM, Vol. 4, N. 4, 2008 (MAF Servizi srl ed.)
Page(s): 259-264
Background. Alzheimer’s disease (AD) is the most common form of dementia and its clinical differentiation from fronto-temporal dementia (FTD) is often difficult. Cerebro-spinal fluid (CSF) Tau, p-Tau and βamyloid1-42 (βA1-42) concentrations seem to be a valid support in clinical diagnosis. Our goal is to analyse the CSF Tau, p-Tau e βA1-42 concentrations and their ratio to identify early-onset AD from subjects with FTD. Methods. 82 CSF samples collected with lumbar puncture: 43 from subjects with probable AD (NINCDSADRA criteria) and 39 from subjects with probable FTD (Neary criteria). Tau, p-Tau and βA1-42 concentrations have been tested with ELISA test (Innotest, Innogenetics, Ghent, Belgium). Results. Only βA1-42 and p-Tau concentrations have shown statistically significant differences between AD and FTD subjects (βA1-42 AD: 383±169 ng/L, FTD: 510±288 ng/L, p=0.05 and p-Tau AD: 92±45 ng/L, FTD: 70±46 ng/L, p=0.002). The graphic combination of Tau, p-Tau e βA1-42 has confirmed the clinical suspect of AD in 34/43 samples (sensitivity: 79%, specificity: 69%). FTD clinical suspect has been confirmed in 19/39 samples (sensitivity: 49%, specificity: 88%). Our data indicate the ratio βA1-42/Tau and βA1-42/pTau as clinically significant to discriminate AD from FTD (p=0.002 and p<0.0001 respectively). Conclusions. CSF p-Tau e βA1-42 concentrations and their ratio, although tested on a small number of samples, seems to be a further support to assist clinician in confirming a suspected AD or to exclude AD in a case of clinical suspect of FTD.